Will Stevens
Overview
Explore the profile of Will Stevens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
1197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
2.
Pessoa-Amorim G, Goldacre R, Crichton C, Stevens W, Nunn M, King A, et al.
Trials
. 2024 Jul;
25(1):429.
PMID: 38951929
Background: Randomised trials are essential to reliably assess medical interventions. Nevertheless, interpretation of such studies, particularly when considering absolute effects, is enhanced by understanding how the trial population may differ...
3.
Preiss D, Logue J, Sammons E, Zayed M, Emberson J, Wade R, et al.
NEJM Evid
. 2024 Jun;
3(8):EVIDoa2400179.
PMID: 38905569
Background: Findings from cardiovascular outcome trials suggest that fenofibrate therapy may reduce the progression of diabetic retinopathy. Methods: We recruited and followed adults with nonreferable diabetic retinopathy or maculopathy using...
4.
Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J, et al.
N Engl J Med
. 2022 Nov;
388(2):117-127.
PMID: 36331190
Background: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the...
5.
Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al.
N Engl J Med
. 2018 Aug;
379(16):1540-1550.
PMID: 30146932
Background: Increased intake of n-3 fatty acids has been associated with a reduced risk of cardiovascular disease in observational studies, but this finding has not been confirmed in randomized trials....
6.
Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al.
N Engl J Med
. 2018 Aug;
379(16):1529-1539.
PMID: 30146931
Background: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of...
7.
Bopp J, Miklowitz D, Goodwin G, Stevens W, Rendell J, Geddes J
Bipolar Disord
. 2010 Jun;
12(3):327-34.
PMID: 20565440
Objectives: To examine the feasibility of collecting course of illness data from patients with bipolar I and II disorder, using weekly text-messaged mood ratings, and to examine the time trajectory...